CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2018--
Inc. (NASDAQ:BIIB) today announced it will report first quarter 2018
financial results on Tuesday, April 24, 2018, before the financial
Following the release of the financials, the Company will host a live
webcast with Biogen management from 8:30-9:30 am ET. To access the live
webcast, please go to the investors section of Biogen’s website.
Following the live webcast, an archived version of the call will be
available on the website.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen
discovers, develops, and delivers worldwide innovative therapies for
people living with serious neurological and neurodegenerative diseases.
Founded in 1978 as one of the world’s first global biotechnology
companies by Charles Weissman, Heinz Schaller, Kenneth Murray and Nobel
Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the
leading portfolio of medicines to treat multiple sclerosis; has
introduced the first and only approved treatment for spinal muscular
atrophy; and is focused on advancing neuroscience research programs in
Alzheimer’s disease and dementia, multiple sclerosis and
neuroimmunology, movement disorders, neuromuscular disorders, pain,
ophthalmology, neuropsychiatry, and acute neurology. Biogen also
manufactures and commercializes biosimilars of advanced biologics. We
routinely post information that may be important to investors on our
website at www.biogen.com.
To learn more, please visit www.biogen.com
and follow us on social media – Twitter,
View source version on businesswire.com: https://www.businesswire.com/news/home/20180328006032/en/
Source: Biogen Inc.
Karen Jewell, 781-464-2442